Sulzberger Capital Advisors Inc. Sells 350 Shares of Johnson & Johnson (NYSE:JNJ)

Sulzberger Capital Advisors Inc. decreased its position in Johnson & Johnson (NYSE:JNJ) by 11.2% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 2,780 shares of the company’s stock after selling 350 shares during the period. Johnson & Johnson comprises approximately 0.6% of Sulzberger Capital Advisors Inc.’s portfolio, making the stock its 27th biggest holding. Sulzberger Capital Advisors Inc.’s holdings in Johnson & Johnson were worth $461,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Norges Bank bought a new stake in Johnson & Johnson in the fourth quarter valued at $4,390,037,000. Raymond James Financial Inc. bought a new stake in Johnson & Johnson in the fourth quarter valued at $1,339,878,000. GAMMA Investing LLC boosted its holdings in Johnson & Johnson by 24,450.4% in the first quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company’s stock valued at $1,196,596,000 after acquiring an additional 7,185,977 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Johnson & Johnson by 134.5% in the fourth quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company’s stock valued at $1,149,536,000 after acquiring an additional 4,559,147 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in Johnson & Johnson by 12.3% in the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock valued at $4,456,201,000 after acquiring an additional 3,363,235 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.9%

Johnson & Johnson stock opened at $155.02 on Friday. The firm has a 50 day moving average of $153.59 and a 200 day moving average of $153.68. The firm has a market capitalization of $372.99 billion, a price-to-earnings ratio of 23.31, a P/E/G ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.35%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is currently 57.84%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on JNJ. Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Barclays lowered their price objective on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Bank of America lowered their price objective on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, April 10th. Finally, Morgan Stanley raised their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 16th. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.